Davis Rea LTD. Sells 19,920 Shares of Zoetis Inc. $ZTS

Key Points

• Davis Rea LTD. reduced its stake in Zoetis by 43.6%, selling 19,920 shares in Q4 and leaving 25,762 shares worth $3.241 million.
• Zoetis beat quarterly estimates (EPS $1.48 vs. $1.40; revenue $2.39B vs. $2.36B) and set FY2026 guidance of 7.00–7.10 EPS, while analysts have a consensus "Hold" rating with a $152.25 price target.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, yield 1.8%), and institutional investors own roughly 92.8% of the stock.

Davis Rea LTD. reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,762 shares of the company's stock after selling 19,920 shares during the quarter. Davis Rea LTD.'s holdings in Zoetis were worth $3,241,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Halbert Hargrove Global Advisors LLC increased its stake in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock worth $25,000 after buying an additional 144 shares in the last quarter. Global Wealth Strategies & Associates purchased a new stake in Zoetis in the 4th quarter worth $25,000. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis in the 3rd quarter worth $31,000. Lodestone Wealth Management LLC purchased a new stake in Zoetis in the 4th quarter worth $30,000. Finally, Holos Integrated Wealth LLC purchased a new stake in Zoetis in the 4th quarter worth $32,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ZTS shares. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research note on Friday, February 13th. Piper Sandler reiterated a "neutral" rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Leerink Partners reiterated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. BTIG Research reiterated a "buy" rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Finally, Citigroup started coverage on Zoetis in a research note on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price target for the company. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $152.25.

Zoetis Trading Down 1.3%

Shares of Zoetis stock opened at $116.01 on Friday. The firm has a market cap of $48.80 billion, a price-to-earnings ratio of 19.27, a PEG ratio of 1.79 and a beta of 0.98. The business has a 50-day moving average price of $121.02 and a 200-day moving average price of $125.73. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a twelve month low of $113.29 and a twelve month high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis Inc. will post 7.02 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.8%. Zoetis's dividend payout ratio (DPR) is currently 35.22%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.